Indivior Pharmaceuticals, Inc. 8-K

What Happened

• Indivior Pharmaceuticals, Inc. announced on March 12, 2026 that it priced an offering of 0.625% convertible senior notes due 2031. The company filed a press release about the offering as Exhibit 99.1 to its Form 8-K (filed March 13, 2026).

Key Details

• Coupon: 0.625% per annum.
• Maturity: Due in 2031.
• Disclosure: The Form 8-K includes a press release (Exhibit 99.1); it does not itself constitute an offer to sell the notes or shares issuable on conversion.
• Additional terms (offering size, conversion rate/price and other economic terms) were not disclosed in this 8-K.

Why It Matters

• For investors, convertible notes can provide the company with debt financing at a relatively low interest cost (0.625%), while carrying the potential for future equity dilution if notes are converted into common stock.
• Because this filing provides limited terms, investors should look for further filings (prospectus or registration statement) or company disclosures for the full economic terms, offering size, and potential dilution impact.